Investors
Company Profile
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
Financial Reports
Investor presentations
Investor Presentation Jefferies Virtual Healthcare Conference June 3rd, 2020
Investor Presentation May 2020
JP Morgan Healthcare Conference, San Francisco, 15th January 2020
Linzagolix Phase 3 PRIMROSE 2 Trial Results
Investor Presentation 10th Annual Jefferies Global Healthcare Conference 21 November 2019
Investor Presentation November 2019
Cantor Global Healthcare Conference October 4 2019
The H.C. Wainwright 21st Annual Global Investment in NYC – September 10th 2019
Press Releases
ObsEva SA to present at ESHRE Virtual 36th Annual Meeting, July 5-8, 2020
press release
July 3, 2020
Geneva, Switzerland and Boston, MA – July 3, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and…
Read moreObsEva and Yuyuan BioScience Technology Announce Submission of the Pre-IND Dossier for Nolasiban with the Chinese NMPA
press release
July 1, 2020
Geneva, Switzerland and Boston, MA – July 1, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN – a clinical-stage biopharmaceutical…
Read moreObsEva SA to Hold Conference Call Monday, July 6 to Discuss Results from Phase 3 PRIMROSE 1 and PRIMROSE 2 Trials Evaluating Linzagolix in Women with Uterine Fibroids
press release
June 29, 2020
Geneva, Switzerland and Boston, MA – June 29, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical…
Read moreGeneral Meetings
ObsEva Annual General Meeting 2020
June 9, 2020
ObsEva Annual General Meeting 2019
May 8, 2019
Upcoming Events
1 2 Next »Stock Information
Latest Press Release
ObsEva SA to present at ESHRE Virtual 36th Annual Meeting, July 5-8, 2020
Geneva, Switzerland and Boston, MA – July 3, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and…
Read moreInvestor Contact
Media Contact
Media Switzerland & Europe
Mario Corso
Vice President, Investor Relations
+1 857 972 9347 Office
+1 781 366 5726 Mobile
Media United States
Mario Corso
Vice President, Investor Relations
+1 857 972 9347 Office
+1 781 366 5726 Mobile
Contacts
Media Switzerland & Europe
Mario Corso
Vice President, Investor Relations
+1 857 972 9347 Office
+1 781 366 5726 Mobile
Media United States
Mario Corso
Vice President, Investor Relations
+1 857 972 9347 Office
+1 781 366 5726 Mobile
Sign up for news
